Acesso livre
Acesso livre

Emergências e Terapia Intensiva

Estudo randomizado SILENCE | Em pacientes em fim de vida, o butilbrometo de escopolamina subcutâneo profilático reduz a ocorrência de estertor da morte (respiração ruidosa causada pelo muco presente no trato respiratório superior).

8 Out, 2021 | 11:12h

Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (gratuito por tempo limitado)

Entrevista com os autores: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA

 

Comentário no Twitter

 

Estudo randomizado | Estratégia ativa para o diagnóstico de embolia pulmonar não melhorou o desfecho em pacientes hospitalizados com exacerbação de DPOC.

8 Out, 2021 | 11:07h

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

 

Comentário no Twitter

 

Estudo randomizado | Mais um estudo mostra que plasma convalescente não melhora os desfechos em pacientes criticamente doentes com Covid-19.

5 Out, 2021 | 11:32h

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial – JAMA

Commentary: Convalescent plasma futile as treatment for critically ill COVID-19 patients, study finds – University of Pittsburgh

Conteúdos relacionados:

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

Pílula da Merck contra Covid-19 é uma ótima notícia, mas pode não ser uma grande mudança.

5 Out, 2021 | 11:28h

Merck’s Covid-19 pill is great news but may not be a game-changer – CNN

Vídeo | Uma pílula para COVID? Um médico explica o molnupiravir.

5 Out, 2021 | 11:26h

A Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD

Diretriz Científica AHA | Diagnóstico e tratamento de pacientes com lesão miocárdica após cirurgia não cardíaca.

5 Out, 2021 | 11:25h

Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association – Circulation

Comunicado de imprensa: 1 in 5 adults has high levels of heart enzymes after any surgery, monitoring advised – American Heart Association

Comentário: AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery – TCTMD

Hipertensão intra-abdominal e síndrome compartimental abdominal em pacientes criticamente doentes: uma revisão do passado, do presente e dos passos futuros.

5 Out, 2021 | 11:16h

Intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients: A narrative review of past, present, and future steps – Scandinavian Journal of Surgery

Revisão | Aprimoramento do cuidado de idosos criticamente doentes.

5 Out, 2021 | 11:15h

Optimizing care for critically ill older adults – Canadian Medical Association Journal

[Comunicado de imprensa – ainda não publicado] Merck anuncia que o antiviral oral Molnupiravir reduziu o risco de internação ou morte em cerca de 50%, comparado ao placebo, em pacientes com COVID-19 leve ou moderada.

4 Out, 2021 | 10:38h

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Comentários:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

 

Comentários no Twitter

(fio – clique para saber mais)

 

Trombose e trombocitopenia imune induzidas por vacina: resumo da diretriz NICE.

4 Out, 2021 | 10:36h

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ

Diretriz original: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Conteúdos relacionados:

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.